Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

被引：0

作者：

Gustavo H. Kijak

Bahar Ahani

Douglas Arbetter

Fernando Chuecos

Vancheswaran Gopalakrishnan

Jagadish Beloor

Tyler Brady

Amy Nguyen

Tiffany L. Roe

Nicolette Schuko

Tianhui Zhang

F. D. Richard Hobbs

Francisco Padilla

Elizabeth J. Kelly

Hugh Montgomery

Katie Streicher

机构：

[1] BioPharmaceuticals R&D,Translational Medicine, Vaccines & Immune Therapies

[2] AstraZeneca,Formerly Data Sciences and Quantitative Biology

[3] Bioinformatics,Nuffield Department of Primary Care Health Sciences

[4] Vaccines & Immune Therapies,Formerly Translational Medicine, Vaccines & Immune Therapies

[5] BioPharmaceuticals R&D,Department of Medicine

[6] AstraZeneca,undefined

[7] Biometrics,undefined

[8] Vaccines & Immune Therapies,undefined

[9] BioPharmaceuticals R&D,undefined

[10] AstraZeneca,undefined

[11] Biometrics,undefined

[12] Vaccines & Immune Therapies,undefined

[13] BioPharmaceuticals R&D,undefined

[14] AstraZeneca,undefined

[15] BioPharmaceuticals R&D,undefined

[16] AstraZeneca,undefined

[17] University of Oxford,undefined

[18] Centro de Investigación en Cardiología y Metabolismo,undefined

[19] BioPharmaceuticals R&D,undefined

[20] AstraZeneca,undefined

[21] University College London,undefined

来源：

Infectious Diseases and Therapy | 2023年 / 12卷

关键词：

AZD7442; Cilgavimab; COVID-19; Tixagevimab; Treatment-emergent viral variants;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2691 / 2707

页数：16

共 50 条

[1] Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
Kijak, Gustavo H.
Ahani, Bahar
Arbetter, Douglas
Chuecos, Fernando
Gopalakrishnan, Vancheswaran
Beloor, Jagadish
Brady, Tyler
Nguyen, Amy
Roe, Tiffany L.
Schuko, Nicolette
Zhang, Tianhui
Hobbs, F. D. Richard
Padilla, Francisco
Kelly, Elizabeth J.
Montgomery, Hugh
Streicher, Katie
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2691 - 2707
[2] Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Tuffy, Kevin M.
Ahani, Bahar
Aksyuk, Anastasia A.
Avila, Miles
Brady, Tyler
Kijak, Gustavo H.
Koh, Gavin
Levin, Myron J.
Roe, Tiffany L.
Schuko, Nicolette
Thissen, Jesse
Ustianowski, Andrew
Zhang, Tianhui
Kelly, Elizabeth J.
Streicher, Katie
JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (08): : 1055 - 1059
[3] Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
Hobbs, F. D. Richard
Montgomery, Hugh
Padilla, Francisco
Simon-Campos, Jesus Abraham
Kim, Kenneth
Arbetter, Douglas
Padilla, Kelly W.
Reddy, Venkatesh Pilla
Seegobin, Seth
Streicher, Katie
Templeton, Alison
Viani, Rolando M.
Johnsson, Eva
Koh, Gavin C. K. W.
Esser, Mark T.
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (09) : 2269 - 2287
[4] Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Levin, Myron J.
Ustianowski, Andrew
De Wit, Stephane
Launay, Odile
Avila, Miles
Templeton, Alison
Yuan, Yuan
Seegobin, Seth
Ellery, Adam
Levinson, Dennis J.
Ambery, Philip
Arends, Rosalinda H.
Beavon, Rohini
Dey, Kanika
Garbes, Pedro
Kelly, Elizabeth J.
Koh, Gavin C. K. W.
Near, Karen A.
Padilla, Kelly W.
Psachoulia, Konstantina
Sharbaugh, Audrey
Streicher, Katie
Pangalos, Menelas N.
Esser, Mark T.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23): : 2188 - 2200
[5] Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
F. D. Richard Hobbs
Hugh Montgomery
Francisco Padilla
Jesus Abraham Simón-Campos
Kenneth Kim
Douglas Arbetter
Kelly W. Padilla
Venkatesh Pilla Reddy
Seth Seegobin
Katie Streicher
Alison Templeton
Rolando M. Viani
Eva Johnsson
Gavin C. K. W. Koh
Mark T. Esser
Infectious Diseases and Therapy, 2023, 12 : 2269 - 2287
[6] Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
Roe, Tiffany L.
Brady, Tyler
Schuko, Nicolette
Nguyen, Amy
Beloor, Jagadish
Guest, Johnathan D.
Aksyuk, Anastasia A.
Tuffy, Kevin M.
Zhang, Tianhui
Streicher, Katie
Kelly, Elizabeth J.
Kijak, Gustavo H.
MICROBIOLOGY SPECTRUM, 2023, 11 (02)
[7] Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Stuver, Robert
Shah, Gunjan L.
Korde, Neha S.
Roeker, Lindsey E.
Mato, Anthony R.
Batlevi, Connie L.
Chung, David J.
Doddi, Sital
Falchi, Lorenzo
Gyurkocza, Boglarka
Hamilton, Audrey
Lin, Ya-Hui
Jakubowski, Ann A.
Joffe, Erel
Landau, Heather L.
Lin, Richard J.
Mailankody, Sham
Palomba, M. Lia
Park, Jae H.
Perales, Miguel-Angel
Ponce, Doris M.
V. Ramanathan, Lakshmi
Salles, Gilles A.
Scordo, Michael
Seo, Susan K.
Shah, Urvi A.
Stein, Eytan M.
Straus, David
Usmani, Saad Z.
Young, James W.
Zelenetz, Andrew D.
Noy, Ariela
Vardhana, Santosha A.
CANCER CELL, 2022, 40 (06) : 590 - 591
[8] Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
Hobbs, F. D. Richard
Montgomery, Hugh
Padilla, Francisco
Simon-Campos, Jesus Abraham
Arbetter, Douglas
Seegobin, Seth
Kiazand, Alexandre
Streicher, Katie
Martinez-Alier, Nuria
Cohen, Taylor S.
Esser, Mark T.
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (03) : 521 - 533
[9] Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
F. D. Richard Hobbs
Hugh Montgomery
Francisco Padilla
Jesus Abraham Simón-Campos
Douglas Arbetter
Seth Seegobin
Alexandre Kiazand
Katie Streicher
Nuria Martinez-Alier
Taylor S. Cohen
Mark T. Esser
Infectious Diseases and Therapy, 2024, 13 : 521 - 533
[10] Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection
Ignacio, Rachel A. Bender
Wohl, David A.
Arends, Rosalin
Reddy, Venkatesh Pilla
Mu, Ying
Javan, Arzhang Cyrus
Hughes, Michael D.
Eron, Joseph J.
Currier, Judith S.
Smith, Davey
Chew, Kara W.
Gibbs, Michael
Fletcher, Courtney, V
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1207 - 1213

← 1 2 3 4 5 →